HER2: a 'predictive factor' ready to use in the daily management of breast cancer patients?
| Data(s) |
01/09/2000
|
|---|---|
| Resumo |
The past few years have witnessed an exponential increase in studies trying to identify molecular markers in patients with breast tumours that might predict for the success or failure of hormonal therapy or chemotherapy. HER2, a tyrosine kinase membrane receptor of the epidermal growth factor receptor family, has been the most widely studied marker in this respect. This paper attempts to critically review to what extent HER2 may improve 'treatment individualisation' for the breast cancer patient. Copyright (C) 2000. Journal Article Review info:eu-repo/semantics/published |
| Formato |
No full-text files |
| Identificador |
uri/info:doi/10.1016/S0959-8049(00)00162-3 uri/info:pii/S0959-8049(00)00162-3 uri/info:pmid/10974622 local/VX-005572 http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/55771 |
| Idioma(s) |
en |
| Fonte |
European journal of cancer, 36 (14 |
| Palavras-Chave | #Sciences bio-médicales et agricoles #Anthracyclines -- therapeutic use #Antineoplastic Agents, Hormonal -- therapeutic use #Antineoplastic Combined Chemotherapy Protocols -- administration & dosage #Antineoplastic Combined Chemotherapy Protocols -- therapeutic use #Breast Neoplasms -- diagnosis #Breast Neoplasms -- metabolism #Breast Neoplasms -- therapy #Chemotherapy, Adjuvant #Cisplatin -- administration & dosage #Drug Resistance, Neoplasm #Female #Fluorouracil -- administration & dosage #Humans #Methotrexate -- administration & dosage #Predictive Value of Tests #Receptor, erbB-2 -- metabolism #Tamoxifen -- therapeutic use #Tumor Markers, Biological -- metabolism |
| Tipo |
info:eu-repo/semantics/article info:ulb-repo/semantics/articlePeerReview info:ulb-repo/semantics/openurl/article |
